BridgeBio Oncology Posts $34.2 Million Net Loss in Third Quarter of 2026
Key Facts
BridgeBio Oncology Therapeutics reported a net loss of $34.2 million in the third quarter of 2026, compared with $44.8 million in the same period of 2025, according to a company statement published via GlobeNewswire on November 10. The company continues to develop oncology treatments but has yet to post quarterly profits. Its results also showed year-over-year declines in research and development and general and administrative expenses. The company said its cash, cash equivalents and marketable securities were expected to fund operations through 2029. Before the results announcement, its shares closed at $2.30 on November 9, according to EL7 data.
Research and development expenses fell to $29.6 million in the third quarter from $35.1 million a year earlier. The company attributed the decline mainly to lower expenses related to programs that had advanced to the clinical stage. This item reflects spending on developing and testing treatments, while the statement did not tie the change to any particular drug program. These expenses remained the largest operating expense component cited in the results. The lower net loss therefore coincided with reduced research and development spending compared with the third quarter of 2025.
General and administrative expenses fell to $7.9 million from $14.1 million in the third quarter of 2025. The company cited lower salary and personnel costs among the reasons for the decline. It also compared current expenses with a period that included a $7.8 million charge related to shares payable to BridgeBio Pharma, recorded in the third quarter of 2025. This means the year-over-year comparison was partly affected by the charge in the prior period. These lower expenses, alongside reduced spending on clinical programs, help explain the decline in the net loss.
The net loss was $34.2 million, down from $44.8 million a year earlier, but the company remained loss-making for the quarter. A comparison of net loss alone is not enough to establish a broad improvement in financial performance, as the company remains unprofitable based on the reported figures. On the funding side, cash, cash equivalents and marketable securities totaled $315.3 million as of September 30, 2026. BridgeBio Oncology said this balance was "expected to provide cash runway for operations through 2029." The company’s runway estimate is tied to its liquidity level at that date as it continues developing its treatment programs.
In a clinical update dated September 2026, the company said BBO-8520 in combination with pembrolizumab achieved an objective response rate of 75% at a dose of 500 mg once daily in patients with non-small cell lung cancer who had previously received a KRAS G12C inhibitor. The rate was 53% across dose levels among 17 patients. In a separate group of patients with non-small cell lung cancer who had not previously received that inhibitor, BBO-8520 alone recorded an objective response rate of 63%, with responses in 26 of 41 patients. The disease control rate in the same group was 100%, or 41 of 41 patients. These results form part of the company’s clinical updates alongside its quarterly financial figures.
The company expects to update data for monotherapy with both BBO-11818 and BBO-10203 in the fourth quarter of 2026. It said combination cohorts for the two drugs are enrolling patients in trials that include colorectal cancer and pancreatic ductal adenocarcinoma. The anticipated update places the clinical development pipeline among the company’s next milestones following its third-quarter results announcement. The statement did not specify a date for the data release during the quarter. The timing comes as the company expects its operating liquidity to last through 2029.